货号:GS40804
Vulinacimab (HLX-06) is an investigational humanized monoclonal antibody of the IgG1-kappa isotype that targets vascular endothelial growth factor receptor 2 (VEGFR-2). It is being developed as an anti-angiogenic therapy for solid tumors, aiming to inhibit the formation of new tumor blood vessels by blocking the primary receptor for VEGF-mediated signaling.
武汉迈思生物科技有限公司
联系商家时请提及chemicalbook,有助于交易顺利完成!
迈思生物